Recently I contacted Imugene through their shareholder email to enquire about the TAMP collaboration with RenovoRx, the below question and response is unedited, except for removal of name.
Apologies if this question has been asked previously and replied to, I have many people on ignore therefore may have missed another post asking the same question.
Hello, Could the company confirm if there is still a collaboration with RenovoRX using its TAMP technology to deliver CF33 to difficult to find cancer cells?
If a collaboration is not still in play is this due primarily to company priorities?
Kind Regards
Dear ,
Unfortunately, under the selective disclosure obligations of the ASX we are unable to respond to enquiries in a private email about matters which are not in the public domain.
We will continue to promptly disclose any material developments to the market as they arise.
We would like to reach the optimal biological dose or recommended phase 2 dose before combining or using a medical device from RenovoRX.
This required further financial and regulatory support from IMU so the decision was to focus on our current trials under our control.
Best Regards,
Imugene
It struck me as odd that they at first gave the standard response about not disclosing information in a private email, but then basically answering my question.
Anyway suffice to say it is not good or bad news as they did not rule out entirely, that following achievement of RP2D, and with better financial position, they could in theory go back to RenovoRx with a proposal to renew a trial.
DYOR opinion only
(20min delay)